← Back to Clinical Trials
Recruiting NCT05194254

NCT05194254 MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05194254
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition ASD
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2022-01-04
Primary Completion 2025-06

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 20 Years
Study Type INTERVENTIONAL
Interventions
MRI-ET

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2022-01-04 with a primary completion date of 2025-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.

Eligibility Criteria

Inclusion Criteria: For the group of people with Autism Spectrum Disorders (experimental group): * Age between 10 to 20 years old * Diagnosis of ASD (CARS) ≥ 30 performed at inclusion * IQ test evaluation (regardless of the result) performed by a trained psychologist * Obtaining informed oral and written consent after appropriate information * Obtaining informed oral and written consent from the legal guardian after information * Be affiliated with social security * No contraindication to magnetic resonance imaging For the TD (Typical Development) group of people (control group): * Age between 10 to 20 years old * Diagnosis of ASD (CARS) \<30 performed at inclusion * IQ test evaluation (regardless of the result) performed by a trained psychologist * Obtaining informed oral and written consent after appropriate information * Obtaining informed oral and written consent from the legal guardian after information * Be affiliated with social security * No contraindication to magnetic resonance imaging Exclusion Criteria: For all groups: * Age outside the range 10 to 20 years * Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.) * Person suffering from major obesity (\> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter \<70cm) * Pregnant or breastfeeding woman * Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision For TD people (control group): * Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia. * Person with a neurological history such as epilepsy and / or neurovascular accident.

Contact & Investigator

Central Contact

Jean-Marc Constans, Pr

✉ constans.jean-marc@chu-amiens.fr

📞 03 22 08 75 15

Frequently Asked Questions

Who can join the NCT05194254 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 20 Years, studying ASD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05194254 currently recruiting?

Yes, NCT05194254 is actively recruiting participants. Contact the research team at constans.jean-marc@chu-amiens.fr for enrollment information.

Where is the NCT05194254 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT05194254 clinical trial?

NCT05194254 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 68 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology